Publications

Clinical Trials and Research Studies

“Meso-tetra (4-carboMeso-tetra (4-carboxyphenyl) porphyrin (TCPP) is taken up in cancer cells by the CD320 receptor” at the International Conference on Porphyrins and Phthalocyanines (ICPP) ICPP-11, June 26 through July 2, 2021

The poster presents the novel mechanism by which the porphyrin TCPP, which is used in bioAffinity Technologies’ non-invasive test for the early detection of lung cancer, is incorporated into cancer cells. These discoveries have furthered our understanding of TCPP for use in diagnostics including the Company’s first product, CyPath® Lung, a flow cytometry test used to diagnose lung cancer at early stage.

read more

“Selective Cancer Cell Killing by Dual siRNA Knockdown of CD320 and LRP2 Receptors” RNA Therapeutics Institute’s 2021 RNA Therapeutics Symposium at the University of Massachusetts Medical School June 23 – 25, 2021

The presentation explains bioAffinity Technologies’ discovery of a fundamental vulnerability of cancer opens the way to new therapies that kill cancer without harm to normal tissue. In particular, bioAffinity’s research shows how the Company has designed and used siRNAs to kill multiple cancers at the cellular level including prostate, lung, breast, brain and skin cancers without harm to normal cells.

read more

“Simultaneous knockdown of CD320 and LRP2 receptors is selectively toxic to cancer cells but not normal cells,” American Association of Cancer Research (AACR) Annual Meeting 2021, April-May, 2021

The presentation reports on research leading to selective killing of cancer cells without harm to normal cells. During efforts to elucidate the mechanism by which TCPP selectively accumulates in cancer cells, we discovered that simultaneous knock down of two LDLR-family receptors was selectively cytotoxic to cancer cells and not to normal cells.

read more